Psychiatry

News

Neurocrine slides as schizophrenia data disappoints

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.

News

prescription digital therapeutic on a smartphone

Otsuka, Click's depression DTx launches in the US

An FDA-approved digital therapeutic (DTx) that can be used to help people living with major depressive disorder (MDD) has been launched in the US and is available in mobile app stores.

News

Article retractions muddy MDMA waters after FDA denial

The journal Psychopharmacology has retracted three articles about MDMA-assisted psychotherapy, shortly after the FDA rejected approval of Lykos Therapeutics' therapy for post-traumatic stre

News

J&J files to expand label of depression drug Spravato

Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression

News

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

AbbVie has agreed to pay $65 million on an option deal with start-up Gilgamesh Pharma, lining up rights to neuroplastogen compounds that can improve neuroplasticity - the

News

Intra-Cellular sets up $500m offer on Caplyta depression win

Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p

Neurocrine slides as schizophrenia data disappoints

Otsuka, Click's depression DTx launches in the US

Article retractions muddy MDMA waters after FDA denial

J&J files to expand label of depression drug Spravato

AbbVie takes option on Gilgamesh CNS drugs in $2bn deal

Intra-Cellular sets up $500m offer on Caplyta depression win

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Psychiatry

Editor's Picks